These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 18937663)

  • 21. Adverse skin reactions due to pegylated interferon alpha 2b plus ribavirin combination therapy in a patient with chronic hepatitis C virus.
    Hashimoto Y; Kanto H; Itoh M
    J Dermatol; 2007 Aug; 34(8):577-82. PubMed ID: 17683392
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of two PEG-interferon alpha-2b doses (1.0 or 1.5 microg/kg) combined with ribavirin in interferon-naïve patients with chronic hepatitis C and up to moderate fibrosis.
    Meyer-Wyss B; Rich P; Egger H; Helbling B; Müllhaupt B; Rammert C; Gonvers JJ; Oneta C; Criblez D; Rossi L; Borovicka J; Meyenberger C; Arn M; Renner EL;
    J Viral Hepat; 2006 Jul; 13(7):457-65. PubMed ID: 16792539
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Sweet syndrome associated with interferon.
    Rodriguez-Lojo R; Castiñeiras I; Juarez Y; Lueiro M; Armesto A; Fernandez-Diaz ML
    Dermatol Online J; 2014 Dec; 21(2):. PubMed ID: 25756490
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Therapy of chronic hepatitis C].
    Ferenci P
    Wien Med Wochenschr; 2000; 150(23-24):481-5. PubMed ID: 11205179
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Incidence and severity of infections according to the development of neutropenia during combined therapy with pegylated interferon-alpha2a plus ribavirin in chronic hepatitis C infection.
    Juarez-Navarro A; Vera-de-León L; Navarro JM; Chirino-Sprung R; Díaz-Hernandez M; Casillas-Davila L; Dehesa-Violante M
    Methods Find Exp Clin Pharmacol; 2005 Jun; 27(5):317-22. PubMed ID: 16082419
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Therapy of hepatitis C].
    Moradpour D; Blum HE
    Praxis (Bern 1994); 2002 May; 91(22):977-82. PubMed ID: 12094432
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Recurrent myocardial ischaemia during combination antiviral therapy in a patient with chronic hepatitis C and normal aminotransferase levels.
    Lenci I; Piccolo P; Francioso S; Di Paolo D; Galante A; Angelico M
    Dig Liver Dis; 2008 Sep; 40(9):785-90. PubMed ID: 17913610
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reversible alopecia universalis secondary to PEG-interferon alpha-2b and ribavirin combination therapy in a patient with chronic hepatitis C virus infection.
    Kartal ED; Alpat SN; Ozgunes I; Usluer G
    Eur J Gastroenterol Hepatol; 2007 Sep; 19(9):817-20. PubMed ID: 17700271
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Side effect of pegylated-interferon treatment in chronic C hepatitis: agranulocytosis].
    Halász T; Farkas A; Tolvaj G; Horváth G
    Orv Hetil; 2006 Feb; 147(7):321-4. PubMed ID: 17489160
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Incidence of neutropenia and infections during combination treatment of chronic hepatitis C with pegylated interferon alfa-2a or alfa-2b plus ribavirin.
    Antonini MG; Babudieri S; Maida I; Baiguera C; Zanini B; Fenu L; Dettori G; Manno D; Mura MS; Carosi G; Puoti M
    Infection; 2008 Jun; 36(3):250-5. PubMed ID: 18458815
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Uterine sarcoidosis potentially associated with interferon-alpha use for chronic hepatitis C infection.
    Tsiodras S; Drimala P; Stavreas N; Dachlythras M; Alamani AM; Naoum G
    Obstet Gynecol; 2005 May; 105(5 Pt 2):1198-201. PubMed ID: 15863580
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Cutaneous sarcoidosis during pegylated interferon alpha and ribavirin treatment of chronic hepatitis C--a case report].
    Honsová E; Sticová E; Sperl J
    Cesk Patol; 2007 Jan; 43(1):27-30. PubMed ID: 17370474
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combination therapy with interferon-alpha 2b and ribavirin for the treatment of relapse patients and non-responders with chronic HCV infection.
    Kallinowski B; Liehr H; Moeller B; Stremmel W; Wechsler JG; Wiese M; Goeser T
    Z Gastroenterol; 2001 Mar; 39(3):199-204, 206. PubMed ID: 11324136
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Manifestation of sarcoidosis during interferon and ribavirin therapy for chronic hepatitis C: a report of two cases.
    Gitlin N
    Eur J Gastroenterol Hepatol; 2002 Aug; 14(8):883-5. PubMed ID: 12172411
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Diabetic ketoacidosis induced by alpha interferon and ribavirin treatment in a patient with hepatitis C.
    Bhatti A; McGarrity TJ; Gabbay R
    Am J Gastroenterol; 2001 Feb; 96(2):604-5. PubMed ID: 11232722
    [No Abstract]   [Full Text] [Related]  

  • 36. A dose-ranging study of pegylated interferon alfa-2b and ribavirin in chronic hepatitis C. The Hepatitis C Intervention Therapy Group.
    Glue P; Rouzier-Panis R; Raffanel C; Sabo R; Gupta SK; Salfi M; Jacobs S; Clement RP
    Hepatology; 2000 Sep; 32(3):647-53. PubMed ID: 10960463
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pegylated interferon alpha-2a and ribavirin combination therapy in HCV liver transplant recipients. Experience of 7 cases.
    Iacob S; Gheorghe L; Hrehoret D; Becheanu G; Herlea V; Popescu I
    J Gastrointestin Liver Dis; 2008 Jun; 17(2):165-72. PubMed ID: 18568137
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pegylated interferon: new preparation. Chronic hepatitis C: advantageous for some patients, but more data needed.
    Prescrire Int; 2003 Dec; 12(68):206-10. PubMed ID: 14986684
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pyoderma gangrenosum and exacerbation of psoriasis resulting from pegylated interferon alpha and ribavirin treatment of chronic hepatitis C.
    Yurci A; Guven K; Torun E; Gursoy S; Baskol M; Akgun H; Ozbakir O; Yucesoy M
    Eur J Gastroenterol Hepatol; 2007 Sep; 19(9):811-5. PubMed ID: 17700270
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Sarcoidosis following combined ribavirin and interferon therapy: a case report and review of the literature].
    Alfageme Michavila I; Merino Sánchez M; Pérez Ronchel J; Lara Lara I; Suárez García E; López Garrido J
    Arch Bronconeumol; 2004 Jan; 40(1):45-9. PubMed ID: 14718122
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.